Modality
Gene Therapy
MOA
AHRant
Target
FXIa
Pathway
Lipid Met
Cervical CaEwing SarcomaLN
Development Pipeline
Preclinical
~Dec 2015
→ ~Mar 2017
Phase 1
Jun 2017
→ Nov 2031
Phase 1Current
NCT07640191
247 pts·LN
2023-12→TBD·Recruiting
NCT08952240
2,447 pts·Cervical Ca
2017-06→2031-11·Terminated
2,694 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-11-085.6y awayPh2 Data· Cervical Ca
Trial Timeline
Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P1/2
Termina…
P1/2
Recruit…
Catalysts
Ph2 Data
2031-11-08 · 5.6y away
Cervical Ca
RecruitingTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07640191 | Phase 1/2 | LN | Recruiting | 247 | PASI75 |
| NCT08952240 | Phase 1/2 | Cervical Ca | Terminated | 2447 | HAM-D |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1085 | Pfizer | Preclinical | FXIa | |
| RHH-682 | Roche | Phase 2 | FXIa | |
| RHH-7975 | Roche | Phase 3 | FXIa | |
| Gozelemzoparlimab | Merck & Co | Phase 2 | FXIa | |
| AZN-5978 | AstraZeneca | Phase 2/3 | GIP-R | |
| Pexazasiran | Sanofi | Preclinical | FXIa | |
| Rimaosocimab | Amgen | Preclinical | FXIa | |
| GIL-9142 | Gilead Sciences | Phase 1 | FXIa | |
| BII-5449 | Biogen | Phase 3 | FXIa | |
| BGN-8936 | BeiGene | Phase 1/2 | FXIa |